Research Topics
| Shanu ModiSummaryAffiliation: Memorial Sloan-Kettering Cancer Center Country: USA Publications
| Collaborators
|
Detail Information
Publications
HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumabShanu Modi
Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Clin Cancer Res 17:5132-9. 2011..On the basis of these data and activity in a phase I study, we conducted a phase II study of 17-AAG (tanespimycin) with trastuzumab in advanced trastuzumab-refractory HER2-positive breast cancer...
Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation studyShanu Modi
Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 25:5410-7. 2007..This phase I study examined whether a heat shock protein (Hsp) 90 inhibitor tanespimycin (17-AAG; KOS-953) could be administered safely in combination with trastuzumab at a dose that inhibits Hsp90 function in vivo in lymphocytes...- Phosphorylated/activated HER2 as a marker of clinical resistance to single agent taxane chemotherapy for metastatic breast cancerShanu Modi
Memorial Sloan-Kettering Cancer Center, New York, New York, USA
Cancer Invest 23:483-7. 2005..046). Functional assessment of HER2 status may provide unique predictive information not seen with conventional assessments... - A phase I study of cetuximab/paclitaxel in patients with advanced-stage breast cancerShanu Modi
Department of Medicine, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Clin Breast Cancer 7:270-7. 2006.... - Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxaneMonica N Fornier
Breast Cancer Medicine Service, Division of Solid Tumor Oncology, Department of Medicine Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
Cancer 104:1575-9. 2005.... - A phase II trial of gemcitabine in patients with metastatic breast cancer previously treated with an anthracycline and taxaneShanu Modi
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Clin Breast Cancer 6:55-60. 2005..The activity and safety reported in this trial are consistent with previous reports in similar patients... - A feasibility study of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (AC) followed by nanoparticle albumin-bound paclitaxel in early-stage breast cancerHeather L McArthur
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, New York 10065, USA
Clin Cancer Res 17:3398-407. 2011..We evaluated the cardiac safety of bevacizumab plus dose-dense doxorubicin-cyclophosphamide (ddAC) → nanoparticle albumin-bound (nab)-paclitaxel in human epidermal growth factor receptor 2 normal early-stage breast cancer... - A phase II trial of imatinib mesylate monotherapy in patients with metastatic breast cancerShanu Modi
Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA
Breast Cancer Res Treat 90:157-63. 2005..CONCLUSION: Imatinib therapy at doses of 800 mg/day was associated with significant toxicity in patients with heavily pre-treated MBC. Our results do not indicate activity for imatinib monotherapy in these unselected patients... 
Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast CancerSarat Chandarlapaty
Human Oncology and Pathogenesis Program, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
Clin Cancer Res 18:6784-91. 2012..We conducted a prospective tissue acquisition study to determine if there is evidence for these lesions in metastatic tumors that have progressed on trastuzumab-containing therapy...- Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan resultsPatrick G Morris
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
Clin Breast Cancer 10:33-9. 2010..A prospective clinical study was designed to explore this hypothesis. Patients and.. - An update on epidermal growth factor receptor inhibitorsShanu Modi
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
Curr Oncol Rep 4:47-55. 2002..Promising new compounds in the advanced stages of clinical testing are emphasized... - Preoperative chemotherapy for breast cancer: miracle or mirage?Clifford Hudis
Breast Cancer Medicine Service, Memorial Sloan Kettering Cancer Center, Weill College of Medicine, Cornell University, New York, New York 10024, USA
JAMA 298:2665-7. 2007 - Single-agent gemcitabine in the treatment of advanced breast cancerShanu Modi
Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
Clin Breast Cancer 4:S101-6. 2004.... - A phase I dose-escalation trial of trastuzumab and alvespimycin hydrochloride (KOS-1022; 17 DMAG) in the treatment of advanced solid tumorsKomal Jhaveri
Memorial Sloan Kettering Cancer Center Weill Cornell Medical College, New York, NY 10032, USA
Clin Cancer Res 18:5090-8. 2012.... - Prospective exploratory analysis of the association between tumor response, quality of life, and expenditures among patients receiving paclitaxel monotherapy for refractory metastatic breast cancerShanu Modi
Breast Cancer Medicine Service, Department of Biostatistics and Epidemiology, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA
J Clin Oncol 20:3665-73. 2002..07). CONCLUSION: Patients with evidence of tumor response on paclitaxel had a QoL benefit not observed in nonresponders, and this response was associated with a trend for lower overall costs...